A Comparative Study on PRO Symptom Monitoring Approaches
By Staff Writer
August 27, 2024
Introduction
Patients with lung cancer often face a grim prognosis, with nearly half being diagnosed at an advanced stage. The 5-year survival rate for lung cancer varies significantly, ranging from 9% to 64% depending on the cancer stage. For years, lung cancer has remained the leading cause of cancer-related deaths. Recent studies, including the SYMPRO-Lung trial, have explored the use of patient-reported outcome (PRO) symptom monitoring to improve health-related quality of life (HRQOL) in these patients.
Understanding PRO Symptom Monitoring
PRO symptom monitoring involves patients reporting their symptoms, which are then used to guide clinical care. The SYMPRO-Lung trial was the first to demonstrate that a patient-initiated (reactive) approach to PRO symptom monitoring was as effective as a physician-initiated (active) response in improving HRQOL 15 weeks after treatment initiation. This was a pragmatic cluster randomised trial. This patient-centred approach could potentially reduce the workload for healthcare practitioners (HCPs) while maintaining clinical efficacy.
Long-Term Effects of PRO Symptom Monitoring
The study extended the observation period to one year to assess the long-term effects of weekly online PRO symptom monitoring. The trial involved 515 lung cancer patients across 14 hospitals. Results indicated that both reactive and active approaches significantly improved long-term HRQOL. Notably, the reactive approach, which involved sending alerts directly to patients, was less labour-intensive for HCPs.
Survival Benefits and Challenges
Previous studies have shown survival benefits with active PRO symptom monitoring. However, these studies often required additional resources, such as funded nursing staff. The SYMPRO-Lung trial did not find significant differences in progression-free survival (PFS) and overall survival (OS) between the intervention and control groups. The lack of statistical significance could be attributed to the study’s limited power and the flexibility given to patients in the reactive group to decide whether to contact their HCPs.
Figure 1. Progression-Free Survival Results of Patient-Initiated (Reactive) vs Physician-Initiated (Active) Response to Patient-Reported Symptom Monitoring vs Care as Usual (Control)Figure 2. Overall Survival Results of Patient-Initiated (Reactive) vs Physician-Initiated (Active) Response to Patient-Reported Symptom Monitoring vs Care as Usual (Control)
Strengths and Limitations
One of the strengths of this study is its pragmatic design, which allowed for the adaptation of the intervention to the specific workflows of each participating hospital. This broad-scale, multicenter approach enhances the generalisability of the findings. However, the study also had limitations, such as differences in patient characteristics between groups and potential selection bias due to the online nature of the intervention. Future research should focus on addressing these limitations and improving algorithm accuracy to minimise false-positive alerts.
Conclusion
The SYMPRO-Lung trial demonstrates that PRO symptom monitoring can improve long-term HRQOL in lung cancer patients. The reactive approach, where patients initiate contact with their HCPs, proved to be as effective as the active approach and less labour-intensive. While no significant survival benefit was observed, the findings justify further research into the implementation of symptom monitoring in routine lung cancer care. Both reactive and active approaches offer flexibility for HCPs and patients, potentially leading to more sustainable and cost-effective care models.
🚨 *What does the U.S. withdrawing from the WHO mean for global health?*
President Trump’s executive order to begin the withdrawal process raises serious concerns about the future of global health security. From financial disparities to a shift in international partnerships, the implications could reshape our collective ability to combat pandemics and health crises.
Dive into our article to understand the potential impacts on health outcomes and the quest for new alliances.
The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.
Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!
💡 *Are single-visit cervical cancer screenings the key to better health outcomes in high HIV prevalence areas?*
A recent study from KwaZulu-Natal, South Africa reveals that repeat single-visit cervical cancer screening using HPV DNA testing is not only the most effective but also the most cost-effective approach for women living with HIV. This aligns with WHO recommendations for comprehensive cervical cancer elimination strategies.
Explore the insights and implications of this vital research that could transform cervical cancer prevention in resource-limited settings.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
